Home

Tvp19 11omslag kijk verder

Keywords register: schizophrenia

Short report

50th anniversary issue 2008, suppl.2

D. Denys, L. de Haan

25 years antipsychotics: back to the future?, 105 - 109

Essay

2019/9

K. Plasmans, I. Glazemakers, G. Dom

Perinatal mental health care for mothers with schizophrenia in Flanders; where are we still short?, 626 - 634

Klinische Praktijk

2019/6

L. Castelein, J. Steyaert, H. Peeters, G. van Buggenhout

Adolescent with a schizophreniform disorder and recurrent 16p11.2 duplication, 421 - 425

Review article

2019/10

S.K. Spoelstra, L. Visser, H. Knegtering

Cariprazine for acute and maintenance treatment of schizophrenia, 702 - 709

Onderzoeksartikel

2018/8

M. Molag, T. Beckers, H.J.E. van de Mortel

The implementation of the multidisciplinary guidelines for treatment of schizophrenia in teams for flexible assertive community treatment: a retrospective study of patient files, 521 - 526

Short report

2018/3 themanummer Personalised Medicine

W. Veling, I.E.C. Sommer, R. Bruggeman, L. de Haan

Personalised medicine for psychosis, 161 - 165

Review article

2018/12

S.K. Spoelstra, L. Bais, H. Knegtering

The three-monthly paliperidone palmitate depot in the treatment of schizophrenia, 827 - 833

Short report

2017/5

D.P. Muller, L. de Haan

Smoking cessation and schizophrenia, 297 - 301

Short report

2017/1

H.G. van Dijk*, E.A. Dapper*, C.H. Vinkers

SSRIs and depressive symptoms in schizophrenia: a systematic review, 40 - 46

Review article

2016/9

T. Sabbe, J. Detraux, M. De Hert

Prolactin, antipsychotics and breast cancer: is there a connection?, 641 - 649

Essay

2016/7

P.F. Bouvy

Schizophrenia exists: yes / no / don’t know, 513 - 519

Short report

2016/7

D. Muller, F. Schirmbeck, L. de Haan

Recommendations regarding diagnosis and treatment of obsessive-compulsive symptoms in schizophrenia, 529 - 534

Review article

2016/6

S. de Jong, R.J.M. van Donkersgoed, J. Arends, P.H. Lysaker, L. Wunderink, M. van der Gaag, A. Aleman, G.H.M. Pijnenborg

Metacognition in psychotic disorders: from concepts to intervention, 455 - 462

Case report

2016/4

TH. van Oeffelt, E.J.D. Prinsen

Treatment-resistant psychosis due to interaction between ritonavir and olanzapine: case report and literature review, 309 - 313

Review article

2016/2

O. de Wachter, J. De La Asuncion, B. Sabbe, M. Morrens

Social dysfunction in schizotypy, 114 - 121

Review article

2015/3

C.P. Engelhard, G. Touquet, A. Tansens, J. De Fruyt

Alcohol-induced psychotic disorder: a systematic literature review, 192 - 201

Review article

2015/3

P. Martinez-Martinez*, P.C. Molenaar*, M. Losen, C. Hoffmann, J. Stevens, L.D. de Witte, T. van Amelsvoort, J. van Os, B.P.F. Rutten

Auto-immune disorders as a possible cause of neuropsychiatric syndromes, 183 - 191

Short report

2015/11

C.H. Vinkers, I.E. Sommer

Amisulpride: a treatment option for psychotic disorders soon to be available in the Netherlands, 830 - 834

Review article

2015/10

J.D. Blom

The delusion of world catastrophe. Is this classic symptom still relevant today?, 730 - 738

Short report

2015/2 themanummer Bewegingsstoornissen

S. van den Ameele, B. Sabbe, M. Morrens

Characteristics of catatonia in schizophrenia and mood disorders, 94 - 98

Short report

2015/2 themanummer Bewegingsstoornissen

L. Docx, B.G.C. Sabbe, J. Koning, T.Q. Mentzel, P.N. van Harten, M. Morrens

Instrumental registration of psychomotor symptoms in schizophrenia: has the time come to use the technique in clinical practice?, 148 - 153

Short report

2015/2 themanummer Bewegingsstoornissen

D.E. Tenback, P.R. Bakker, P.N. van Harten

Risk factors for tardive movement disorders in schizophrenia, 120 - 124

Review article

2014/6

J. Van Hecke, T.E. Gladwin, J. Coremans, W. Hulstijn, B. Sabbe

Functional MRI for schizophrenia: importance of the type of task being scanned, 385 - 393

New research

2014/6

E. Thys, C.I. Struyven, M. Danckaerts, M. De Hert

The stigmatising of schizophrenia and autism in the Flemish daily papers, 365 - 374

Short report

2014/6

J.E. Hovens, T.A.M. Onderwater

Minocycline for schizophrenia: a brief overview, 402 - 406